Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.

Teofila SeremetYanina JansenSimon PlankenHassan NjimiMélanie DelaunoyHakim El HousniGil AwadaJulia Katharina SchwarzeMarleen KeyaertsHendrik EveraertDanielle LienardVéronique Del MarmolPierre HeimannBart Neyns

Published in: Journal of translational medicine (2019)

Assessment of ctDNA baseline and during therapy was predictive for tumor response and clinical outcome in metastatic melanoma patients and reflected the tumor burden. ctDNA evaluation provided reliable complementary information during anti-PD1 antibody therapy.

Keyphrases

circulating tumor
circulating tumor cells
cell free
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
clinical evaluation
replacement therapy